109170 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar 2'-O-R Modification
COMPOUNDS AND METHODS FOR REDUCING PSD3 EXPRESSION
#902RNA-BASED ADJUVANT TO ENHANCE THE IMMUNE RESPONSE TO VACCINES AND THERAPEUTICS
#903COMPOSITIONS AND METHODS FOR SILENCING SCN9A EXPRESSION
#904Base editing of PCSK9 and methods of using same for treatment of disease
#905ANTISENSE OLIGONUCLEOTIDE OF CALM2
#906RIG-I Agonists and Methods of Using Same
#907Terminal Deoxynucleotidyl Transferase Variants and Uses Thereof
#908CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9
#909Prekallikrein-modulating compositions and methods of use thereof
#910COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#911ANTISENSE NUCLEIC ACIDS
#912DESIGN METHOD FOR OPTIMIZED RIG-I LIGANDS
#913MODULATORS OF GROWTH HORMONE RECEPTOR
#914MULTIMERIC OLIGONUCLEOTIDES WITH DIVIDED STRANDS
#915FORMULATIONS
#916CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS
#917SiRNA molecule inhibiting the expression of the PCSK9 gene and use thereof
#918ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#919COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
#920ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF USHER SYNDROME
#921CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS12B
#922DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF
#923Targeted Inhibition Using Engineered Oligonucleotides
#924EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST
#925ANTISENSE OLIGONUCLEOTIDE OF ATN1
#926MANNAN BINDING LECTIN SERINE PEPTIDASE 2 (MASP2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#927RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
#928UNC13A antisense oligonucleotides
#929Compositions and methods for TTR gene editing and treating ATTR amyloidosis
#930COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#931ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#932Compounds and methods for reducing LRRK2 expression
#933Selective Antisense Compounds and Uses Thereof
#934Compositions for Modulating C9ORF72 Expression
#935METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA
#936Compositions for treatment of polycystic kidney disease
#937Polymerizable compound, compound, and method for producing boranophosphate oligomer
#938METHODS FOR REDUCING HTT EXPRESSION
#939COMPOSITIONS AND METHODS FOR INHIBITING ALPHA-1 ANTITRYPSIN EXPRESSION
#940METHODS OF TREATING SPINAL MUSCULAR ATROPHY
#941PRODRUG INCORPORATED sgRNA SYNTHESIS
#942RNA-Editing Oligonucleotides and Uses Thereof
#943EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#944METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
#945MICRORNA COMPOSITIONS AND METHODS OF USE
#946COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES
#947Exponential base-3 and greater nucleic acid amplification with reduced amplification time
#948ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS
#949Guide RNAs with chemical modification for prime editing
#950Compositions and methods of treating facioscapulohumeral muscular dystrophy
#951Compositions of matter for detection assays
#952PRODUCTS AND COMPOSITIONS
#953ANTISENSE OLIGOMERS AND METHODS FOR TREATING PARKIN-RELATED PATHOLOGIES
#954Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#955RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
#956METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
#957Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
#958APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#959ANTAGONISM AS A THERAPY FOR TDP-43 PROTEINOPATHIES
#960ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
#961UNIVERSAL DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS
#962NEW METHOD FOR TARGETED EDITING OF RNA
#963Methods and compositions for modulating splicing
#964Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
#965Compositions and methods for modulating complement factor B expression
#966ATAXIN3 (ATXN3) RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#967COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#968TREM compositions and uses thereof
#969COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE
#970MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE
#971Polynucleotide compositions and methods for gene expression regulations
#972Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent
#973Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression
#974COMPOSITIONS AND METHODS FOR MODULATING ATAXIN 3 EXPRESSION
#975SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#976SYSTEMS AND METHODS FOR LIPID NANOPARTICLE DELIVERY OF GENE EDITING MACHINERY
#977RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
#978MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
#979Implantable Medical Device for the Delivery of a Nucleic Acid
#980COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#981Modulation of huntingtin expression
#982Oligonucleotides for SARS-CoV-2 modulation
#983EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS
#984Modulators and modulation of the receptor for advanced glycation end-products RNA
#985RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
#986RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use
#987RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
#988PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#989Compounds and methods for modulating factor XII
#990Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
#991RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
#992CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY
#993METHODS FOR TREATING HEPATITIS B INFECTION
#994PIKFYVE antisense oligonucleotides
#995RNA MOLECULE, CHIMERIC NA MOLECULE, DOUBLE-STRANDED RNA MOLECULE, AND DOUBLE-STRANDED CHIMERIC NA MOLECULE
#996Twist signaling inhibitor compositions and methods of using the same
#997COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION
#998Compounds and methods for modulating UBE3A-ATS
#999Compositions and methods of treating muscle dystrophy
#1000Modulation of Angiopoietin-Like 3 Expression
#1001MODULATING GENOMIC COMPLEXES
#1002Selective reduction of allelic variants
#1003METHODS AND COMPOSITIONS FOR MODULATING SPLICING
#1004COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#1005COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1006MODIFIED iRNA AGENTS
#1007Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#1008LAG3 binding peptides
#1009Allele-specific silencing therapy for DFNA9 using antisense oligonucleotides
#1010CHEMICAL MODIFICATIONS OF SMALL INTERFERING RNA WITH MINIMAL FLUORINE CONTENT
#1011Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
#1012RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
#1013CONJUGATES AND METHODS FOR TREATING LIVER FIBROSIS
#1014Organic compositions to treat HSF1-related diseases
#1015ASYMMETRIC SIRNA INHIBITING EXPRESSION OF PD-1
#1016COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#1017RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#1018Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
#1019SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES
#1020COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
#1021Modified antisense oligonucleotide for inhibition of FoxP3 expression
#1022Dynamic pharmacokinetic-modifying anchors
#1023Inhibitors Of RNA Editing And Uses Thereof
#1024FN3 domain-siRNA conjugates and uses thereof
#1025OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
#1026Compositions and methods for modulating PNPLA3 expression
#1027RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1028Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
#1029COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1030ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
#1031PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1032COMPOSITION FOR DIAGNOSIS OR TREATMENT OF A CONDITION ASSOCIATED WITH INCREASED ACTIVITY OF EIF4E COMPRISING AN EIF4E INHIBITOR
#1033GNAQ targeted dsRNA compositions and methods for inhibiting expression
#1034COMPOSITIONS AND METHODS FOR INHIBITING KETOHEXOKINASE (KHK)
#1035OLIGONUCLEOTIDES FOR TREATMENT OF ANGIOPOIETIN LIKE 4 (ANGPTL4) RELATED DISEASES
#1036CHEMICALLY MODIFIED OLIGONUCLEOTIDES FOR RNA EDITING
#1037Antisense nucleic acid that induces skipping of exon 50
#1038TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
#1039Modified RNAi agents
#1040Nucleic acids for inhibiting expression of TMPRSS6 and iron chelators
#1041Methods and systems for guide RNA design and use
#1042ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATING PENDRED SYNDROME
#1043NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#1044COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
#1045RNA-Editing Enzyme-Recruiting Oligonucleotides and Uses Thereof
#1046DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM
#1047ANTISENSE RNA EDITING OLIGONUCLEOTIDES COMPRISING CYTIDINE ANALOGS
#1048RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF
#1049DOUBLE-STRANDED NUCLEIC ACID COMPLEX AND USE THEREOF
#1050METHODS FOR TREATING MUSCULAR DYSTROPHY USING INHIBITORY OLIGONUCLEOTIDES TO CD49D
#1051RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
#1052Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#1053Defined multi-conjugates oligonucleotides
#1054Products and compositions
#1055COMPOSITIONS AND METHODS FOR MODULATING SPLICING AND PROTEIN EXPRESSION
#1056COMPOUNDS AND METHODS USEFUL FOR MODULATING GENE SPLICING
#1057OLIGONUCLEOTIDE THERAPY FOR STARGARDT DISEASE
#1058COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
#1059METHODS AND COMPOSITIONS FOR TREATING MALIGNANT TUMORS ASSOCIATED WITH KRAS MUTATION
#1060RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA)
#1061COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#1062SiRNA structures for high activity and reduced off target
#1063CANCER TREATMENT USING TARGETED siRNA PHARMACEUTICAL FORMULATIONS TO DOWNREGULATE EXPRESSION OF PRDM14 PROTEIN
#1064COMPOSITIONS AND METHODS OF USING C/EBP ALPHA SARNA
#1065SPLICE MODULATING OLIGONUCLEOTIDES TARGETING RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND METHODS OF USE
#1066COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#1067EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1068COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
#1069O-methyl rich fully stabilized oligonucleotides
#1070Methods and compositions for inhibiting PMP22 expression
#1071Modulators of Complement Factor B
#1072Modulators of MALAT1 expression
#1073NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
#1074COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
#1075Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
#1076RNAi Inhibition of Alpha-ENaC Expression
#1077Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1078Antisense oligonucleotides for the treatment of Leber congenital amaurosis
#1079NANOGOLD-DNA BIOCONJUGATES AND METHODS OF USE THEREOF
#1080METHODS AND COMPOSITIONS FOR TREATING PULMONARY ARTERIAL HYPTERNSION
#1081Carboxypeptidase B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1082Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#1083SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1084COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4
#1085COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1086Nucleic acids and methods for the treatment of Pompe disease
#1087Targeted inhibition using engineered oligonucleotides
#1088Oral delivery of antisense conjugates targeting PCSK9
#1089DUAL TARGETING siRNA AGENTS
#1090MODULATION OF TRANSTHYRETIN EXPRESSION
#1091COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
#1092MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#1093Antisense oligonucleotides for the treatment of Stargardt disease
#1094HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1095TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#1096OLIGOMERS
#1097TAU-TARGETING OLIGONUCLEOTIDE GAPMERS
#1098Antisense oligonucleotide and double stranded RNAS for control of hemipteran and lepidopteran pests
#1099RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#1100Compositions for modulating Ataxin 2 expression
#1101OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1102Compositions comprising chemically modified guide RNAs for CRISPR/Cas-mediated editing of HBB
#1103CHEMICALLY MODIFIED GUIDE RNAS FOR CRISPR/CAS-MEDIATED GENE CORRECTION
#1104Chemically modified guide RNAS for CRISPR/Cas-mediated gene regulation
#1105METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF CYP27A1
#1106Linkage modified oligomeric compounds and uses thereof
#1107OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1108COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#1109COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION
#1110Modified short interfering nucleic acid (siNA) molecules and uses thereof
#1111Oligonucleotides for modulating Tau expression
#1112Antisense Oligonucleotides Targeting ATXN3
#1113Methods for treating or preventing ophthalmological conditions
#1114COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION IN THE CENTRAL NERVOUS SYSTEM
#1115ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE
#1116Modulation of prekallikrein (PKK) expression
#1117Nucleic acids for inhibiting expression of LPA in a cell
#1118Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#1119RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1120NUCLEIC ACID COMPLEX FOR MODULATING IHH EXPRESSION
#1121ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#1122ANTISENSE NUCLEIC ACIDS
#1123COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION
#1124OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1125SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
#1126HETERO DOUBLE-STRANDED antimiR
#1127ANTISENSE OLIGONUCLEOTIDE-BASED PROGRANULIN AUGMENTATION THERAPY IN NEURODEGENERATIVE DISEASES
#1128Oligonucleotides for inducing paternal UBE3A expression
#1129TARGETS AND METHODS FOR TREATING EPSTEIN-BARR VIRUS MEDIATED NEURODEGENERATION
#1130ENZYMATIC RNA SYNTHESIS
#1131KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1132CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1133Compositions and methods for treating COVID-19
#1134Methods of modulating RNA translation
#1135OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA
#1136ANTISENSE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING
#1137COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#1138Polycomb-associated Non-Coding RNAs
#1139Modified amine lipids
#1140ANTISENSE OLIGOMERS AND USES THEREOF
#1141PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1142RNAi Inhibition of Alpha-ENaC Expression
#1143COMPOUNDS AND METHODS FOR REDUCING PMP22 EXPRESSION
#1144Modulation of GYS1 expression
#1145CANCER-SPECIFIC MOLECULES AND METHODS OF USE THEREOF
#1146Therapeutic compositions for treating pain via multiple targets
#1147PHOSPHONOACETATE GAPMER OLIGONUCLEOTIDES
#1148Antisense Drug Against the Human Intercellular Adhesion Molecule 1 (ICAM-1)
#1149SPLICE MODULATING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#1150Methods and compositions for editing RNAs
#1151OLIGONUCLEOTIDE
#1152OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1153Methods for Treatment of Alport Syndrome
#1154ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A RETAINED INTRONS
#1155Gapmer antisense oligonucleotides targeting SARS-CoV-2 for treating COVID 19
#1156NOVEL DNA APTAMER AND USE THEREOF
#1157Method for generating aptamers with improved off-rates
#1158HNF4a saRNA compositions and methods of use
#1159Method of treating fatty liver disease
#1160OLIGONUCLEOTIDES FOR HTT-1A MODULATION
#1161Complement component C5 iRNA compositions and methods of use thereof
#1162Products and compositions
#1163GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
#1164Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#1165Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#1166Compounds and Methods for Use in Dystrophin Transcript
#1167RNAi agents for Hepatitis B virus infection
#1168COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS
#1169Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1170Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1171Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1172Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1173Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1174Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1175Aptamers and use thereof
#1176Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat
#1177ARTIFICIAL NUCLEIC ACIDS FOR RNA EDITING
#1178COMPOUNDS AND METHODS FOR MODULATION OF SMN2
#1179METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#1180Bi specific aptamer
#1181COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION
#1182MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#1183Double-stranded RNA molecule targeting CKIP-1 and use thereof
#1184COMPOUNDS AND METHODS FOR MODULATING SMN2
#1185RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use
#1186HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE
#1187PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS
#1188METABOLIC BENEFITS OF SHORT MIR-22 MIRNA ANTAGOMIR THERAPIES
#1189METHODS AND COMPOSITIONS FOR INHIBITION OF CRISPR RE-CLEAVAGE EVENTS
#1190Stabilized CRISPR complexes
#1191Antisense compounds targeting genes associated with cystic fibrosis
#1192Modulating the cellular stress response
#1193COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES
#1194CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
#1195dsRNA Directed to Coronavirus Proteins
#1196Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
#1197MODULATORS OF IRF5 EXPRESSION
#1198Purification methods for guanine-rich oligonucleotides
#1199RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1200APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF